2014.
Under the programme initiated 30 January 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.6 billion in the period from 30 January 2014 to 29 April 2014.
Since the announcement as of 24 February 2014, the following transactions have been made under the programme:
24 February 2014 230,000 244.91 56,329,530
25 February 2014 222,000 255.69 56,763,047
26 February 2014 225,000 257.63 57,965,760
27 February 2014 230,000 258.37 59,425,192
28 February 2014 220,000 256.82 56,500,554
With the transactions stated above, Novo Nordisk owns a total of 109,392,786 treasury shares, corresponding to 4.0% of the share capital. The total amount of shares in the
company is 2,750,000,000 including treasury shares.
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 13 / 2014
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 28 February 2014, Novo Nordisk
has repurchased a total of 5,895,995 B shares equal to a transaction value of DKK
1,377,225,119.
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B
shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com.
Further information Media: Anne Margrethe Hauge Ken Inchausti (US) | +45 4442 3450 +1 609 514 8316 | amhg@novonordisk.com kiau@novonordisk.com |
Investors: Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Frank Daniel Mersebach Lars Borup Jacobsen Daniel Bohsen Jannick Lindegaard (US) | +45 3079 0604 +45 3075 3479 +45 3079 6376 +1 609 235 8567 | fdni@novonordisk.com lbpj@novonordisk.com dabo@novonordisk.com jlis@novonordisk.com |
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 13 / 2014
distributed by |